参考文献/References:
[1]Gaborit B,Sengenes C,Ancel P,et al.Role of Epicardial Adipose Tissue in Health and Disease:A Matter of Fat[J].Compr Physiol,2017(7):1051-1082. [2]Berg G,Miksztowicz V,Morales C,et al.Epicardial Adipose Tissue in Cardiovascular Disease[J].Adv Exp Med Biol,2019(1127):131-143. [3]Chen LK,Woo J,Assantachai P,et al.Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J].J Am Med Dir Assoc,2020(21):300-307.e302. [4]Tsuchida K,Fujihara Y,Hiroki J,et al.Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure[J].Int Heart J,2018,59(1):143-148. [5]Bekfani T,Pellicori P,Morris DA,et al.Sarcopenia in patients with heart failure with preserved ejection fraction:Impact on muscle strength,exercise capacity and quality of life[J].Int J Cardiol,2016(222):41-46. [6]Iacobellis G,Corradi D,Sharma AM.Epicardial adipose tissue:anatomic,biomolecular and clinical relationships with the heart[J].Nat Clin Pract Cardiovasc Med,2005,2(10):536-543. [7]Patel VB,Shah S,Verma S,et al.Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease[J].Heart Fail Rev,2017,22(6):889-902. [8]Antonopoulos AS,Margaritis M,Verheule S,et al.Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-γ/Adiponectin Signalling[J].Circ Res,2016,118(5):842-855. [9]Iacobellis G,Bianco AC.Epicardial adipose tissue:emerging physiological,pathophysiological and clinical features[J].Trends Endocrinol Metab,2011,22(11):450-457. [10]Gruzdeva OV,Akbasheva OE,Dyleva YA,et al.Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease[J].Bull Exp Biol Med,2017,163(5):608-611. [11]Van Dam AD,Boon MR,Berbée JFP,et al.Targeting white,brown and perivascular adipose tissue in atherosclerosis development[J].Eur J Pharmacol,2017(816):82-92. [12]Christensen RH,von Scholten BJ,Hansen CS,et al.Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes[J].Cardiovasc Diabetol,2019,18(1):114. [13]Packer M.Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue[J].Cardiovasc Diabetol,2019,18(1):121. [14]Massalha S,Walpot J,Dey D,et al.Epicardial Adipose Tissue:An Independent Predictor of Post-Operative Adverse Cardiovascular Events(CTA VISION Substudy)[J].JACC Cardiovasc Imaging,2020,13(3):882-884. [15]Aeddula NR,Cheungpasitporn W,Thongprayoon C,et al.Epicardial Adipose Tissue and Renal Disease[J].J Clin Med,2019,8(3):299. [16]Kim IC,Han S.Epicardial adipose tissue:fuel for COVID-19-induced cardiac injury[J].Eur Heart J,2020(41):2334-2335. [17]Srinivasa S,Lu MT,Fitch KV,et al.Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV[J].Antivir Ther,2018,23(1):1-9. [18]Maurice F,Gaborit B,Vincentelli C,et al.Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue[J].J Am Coll Cardiol,2018,72(18):2276-2277. [19]Liu B,Li Y,Li Y,et al.Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis[J].Hepatol Int,2019,13(6):757-765. [20]Lai S,Muscaritoli M,Andreozzi P,et al.Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy[J].Nutrition,2019(62):108-114. [21]Ziyrek M,Kahraman S,Ozdemir E,et al.Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients[J].Rev Port Cardiol,2019,38(6):419-423. [22]Iacobellis G,Gra-Menendez S.Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity[J].Obesity(Silver Spring),2020,28(6):1068-1074. [23]Lima-Martínez MM,Paoli M,Rodney M,et al.Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study[J].Endocrine,2016,51(3):448-455. [24]Raggi P,Gadiyaram V,Zhang C,et al.Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering:A Potential Pleiotropic Effect[J].J Am Heart Assoc,2019,8(12):e013104. [25]Bauer J,Morley JE,Schols A,et al.Sarcopenia:A Time for Action.An SCWD Position Paper[J].J Cachexia Sarcopenia Muscle,2019,10(5):956-961. [26]Beretta MV,Dantas Filho FF,Freiberg RE,et al.Sarcopenia and Type 2 diabetes mellitus as predictors of 2-year mortality after hospital discharge in a cohort of hospitalized older adults[J].Diabetes Res Clin Pract,2020(159):107969. [27]Alemán-Mateo H,López Teros M,Ramírez F,et al.Association between insulin resistance and low relative appendicular skeletal muscle mass:evidence from a cohort study in community-dwelling older men and women participants[J].J Gerontol A Biol Sci Med Sci,2014,69(7):871-877. [28]Schaap L,Pluijm S,Deeg D,et al.Higher inflammatory marker levels in older persons:associations with 5-year change in muscle mass and muscle strength[J].J Gerontol A Biol Sci Med Sci,2009,64(11):1183-1189. [29]Rong YD,Bian AL,Hu HY,et al.Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6,anti-inflammatory cytokine IL-10[J].BMC Geriatr,2018,18(1):308. [30]Bian AL,Hu HY,Rong YD,et al.A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α[J].Eur J Med Res,2017,22(1):25. [31]Yalcin A,Silay K,Balik AR,et al.The relationship between plasma interleukin-15 levels and sarcopenia in outpatient older people[J].Aging Clin Exp Res,2018,30(7):783-790. [32]Bach E,Nielsen R,Vendelbo M,et al.Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo-controlled,bilaterally infused human leg:increased insulin sensitivity, increased net protein breakdown,and increased IL-6 release[J].Diabetes,2013,62(12):4023-4029. [33]Carey AL,Steinberg GR,Macaulay SL,et al.Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase[J].Diabetes,2006,55(10):2688-2697. [34]Wang M,Tan Y,Shi Y,et al.Diabetes and Sarcopenic Obesity:Pathogenesis,Diagnosis,and Treatments[J].Front Endocrinol(Lausanne),2020(11):568. [35]Semba R,Bandinelli S,Sun K,et al.Relationship of an advanced glycation end product,plasma carboxymethyl-lysine,with slow walking speed in older adults:the InCHIANTI study[J].Eur J Appl Physiol,2010,108(1):191-195. [36]Mesinovic J,Zengin A,De Courten B,et al.Sarcopenia and type 2 diabetes mellitus:a bidirectional relationship[J].Diabetes Metab Syndr Obes,2019(12):1057-1072. [37]Schweitzer L,Geisler C,Pourhassan M,et al.What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults[J].Am J Clin Nutr,2015,102(1):58-65. [38]Makanae Y,Fujita S.Role of Exercise and Nutrition in the Prevention of Sarcopenia[J].J Nutr Sci Vitaminol(Tokyo),2015,61(Suppl):S125-S127. [39]Zhu LY,Chan R,Kwok T,et al.Effects of exercise and nutrition supplementation in community-dwelling older Chinese people with sarcopenia:a randomized controlled trial[J].Age Ageing,2019,48(2):220-228. [40]Bauer JM,Verlaan S,Bautmans I,et al.Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults,the PROVIDE study:a randomized,double-blind,placebo-controlled trial[J].J Am Med Dir Assoc,2015,16(9):740-747.